Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study

Nyein PP 1 , Petoumenos K 1 , Borok M 2 , Eriobu N 3 , Kumarasamy N 4 , Avihingsanon A 5 Show all authors , Azwa I 6 , Dao S 7 , Cisse M 8 , Dharan NJ 1 , Hanson J 1 , Matthews GV 1

Affiliations 

  • 1 The Kirby Institute, University of New South Wales, Sydney, Australia
  • 2 University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe
  • 3 International Research Center of Excellence (IREC), Institute of Human Virology Nigeria, Abuja, Nigeria
  • 4 VHS Infectious Diseases Medical Centre, Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS) Voluntary Health Services (VHS), Chennai, India
  • 5 The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Bangkok, Thailand
  • 6 University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia
  • 7 University Clinical Research Centre (UCRC), Bamako, Mali
  • 8 Centre de Traitement Ambulatoire de Donka (Hospital de Jour), Université Gamal Abdel Nasser de Conakry, Conakry, Guinea
Clin Infect Dis, 2025 Feb 05;80(1):160-163.
PMID: 38721980 DOI: 10.1093/cid/ciae256

Abstract

In this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant after controlling for confounding factors, including weight gain.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications